二甲双胍治疗 1 型糖尿病的新视角。
A new perspective on metformin therapy in type 1 diabetes.
机构信息
Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.
Glasgow Royal Infirmary, Glasgow, UK.
出版信息
Diabetologia. 2017 Sep;60(9):1594-1600. doi: 10.1007/s00125-017-4364-6. Epub 2017 Aug 2.
Abstract
Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk of cardiovascular disease.
摘要
二甲双胍在 1 型糖尿病中的应用较为常见，可减少胰岛素的剂量需求。指南建议，超重和肥胖的患者使用二甲双胍可以改善血糖控制，但目前的证据有限。最近发表的 REMOVAL 试验结果表明，二甲双胍治疗 1 型糖尿病可以减少动脉粥样硬化进展、体重和 LDL 胆固醇水平。这为 1 型糖尿病中的二甲双胍治疗提供了新的视角，并提示其可能有助于降低长期心血管疾病风险。
相似文献
1
A new perspective on metformin therapy in type 1 diabetes.
Diabetologia. 2017 Sep;60(9):1594-1600. doi: 10.1007/s00125-017-4364-6. Epub 2017 Aug 2.
2
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.
Diabetes Obes Metab. 2017 Apr;19(4):509-516. doi: 10.1111/dom.12840. Epub 2017 Feb 17.
3
Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: A randomized controlled trial.
Diabetes Res Clin Pract. 2022 Apr;186:109857. doi: 10.1016/j.diabres.2022.109857. Epub 2022 Mar 26.
4
Vascular and metabolic effects of metformin added to insulin therapy in patients with type 1 diabetes: A systematic review and meta-analysis.
Diabetes Metab Res Rev. 2020 Sep;36(6):e3334. doi: 10.1002/dmrr.3334. Epub 2020 May 26.
5
Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus.
Circulation. 2018 Dec 18;138(25):2895-2907. doi: 10.1161/CIRCULATIONAHA.118.035525.
6
What role for metformin in type 1 diabetes?
Drug Ther Bull. 2018 Jul;56(7):78-80. doi: 10.1136/dtb.2018.7.0645.
7
Association between adjunctive metformin therapy in young type 1 diabetes patients with excess body fat and reduction of carotid intima-media thickness.
Pol Arch Med Wewn. 2016 Aug 25;126(7-8):514-20. doi: 10.20452/pamw.3527.
8
Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Drug Des Devel Ther. 2013;7:99-104. doi: 10.2147/DDDT.S38346. Epub 2013 Feb 14.
9
Effect of Metformin on Vascular Function in Children With Type 1 Diabetes: A 12-Month Randomized Controlled Trial.
J Clin Endocrinol Metab. 2017 Dec 1;102(12):4448-4456. doi: 10.1210/jc.2017-00781.
10
Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes.
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3265-3278. doi: 10.1210/jc.2019-00129.
引用本文的文献
1
An Updated Systematic Review and Meta-Analysis on the Efficacy and Safety of Metformin as Add-on Therapy to Insulin in Patients With Type 1 Diabetes.
Endocrinol Diabetes Metab. 2025 Jul;8(4):e70060. doi: 10.1002/edm2.70060.
2
Major adverse cardiovascular events' reduction and their association with glucose-lowering medications and glycemic control among patients with type 2 diabetes: A retrospective cohort study using electronic health records.
J Diabetes. 2024 Oct;16(10):e13604. doi: 10.1111/1753-0407.13604.
3
Unmet needs in the treatment of type 1 diabetes: why is it so difficult to achieve an improvement in metabolic control?
Nutr Diabetes. 2024 Aug 2;14(1):58. doi: 10.1038/s41387-024-00319-w.
4
Exploring the clinical connections between epilepsy and diabetes mellitus: Promising therapeutic strategies utilizing agmatine and metformin.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec;397(12):9617-9632. doi: 10.1007/s00210-024-03295-1. Epub 2024 Jul 27.
5
Hypoglycemia and anxiolysis mediated by levofloxacin treatment in diabetic rats.
J Diabetes Metab Disord. 2023 Jun 5;22(2):1197-1209. doi: 10.1007/s40200-023-01234-0. eCollection 2023 Dec.
6
Poly(2-Hydroxyethyl Methacrylate) Hydrogel-Based Microneedles for Metformin Release.
Glob Chall. 2023 Jul 5;7(8):2300002. doi: 10.1002/gch2.202300002. eCollection 2023 Aug.
7
Metformin Impedes Oxidation of LDL In Vitro.
Pharmaceutics. 2023 Aug 9;15(8):2111. doi: 10.3390/pharmaceutics15082111.
8
Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes.
Drug Des Devel Ther. 2023 Jun 26;17:1907-1932. doi: 10.2147/DDDT.S409373. eCollection 2023.
9
Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective.
Pharmaceutics. 2022 May 31;14(6):1180. doi: 10.3390/pharmaceutics14061180.
10
Association Between Increased Lipid Profiles and Risk of Diabetic Retinopathy in a Population-Based Case-Control Study.
J Inflamm Res. 2022 Jun 10;15:3433-3446. doi: 10.2147/JIR.S361613. eCollection 2022.
本文引用的文献
1
Metformin: clinical use in type 2 diabetes.
Diabetologia. 2017 Sep;60(9):1586-1593. doi: 10.1007/s00125-017-4336-x. Epub 2017 Aug 2.
2
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
Lancet Diabetes Endocrinol. 2017 Aug;5(8):597-609. doi: 10.1016/S2213-8587(17)30194-8. Epub 2017 Jun 11.
3
Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study.
BMC Nephrol. 2017 May 19;18(1):163. doi: 10.1186/s12882-017-0579-5.
4
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.
Diabetes Obes Metab. 2017 Apr;19(4):509-516. doi: 10.1111/dom.12840. Epub 2017 Feb 17.
5
Severe hypoglycemia rates are not associated with HbA1c: a cross-sectional analysis of 3 contemporary pediatric diabetes registry databases.
Pediatr Diabetes. 2017 Nov;18(7):643-650. doi: 10.1111/pedi.12477. Epub 2016 Nov 23.
6
Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.
BMJ Open. 2016 Feb 25;6(2):e008376. doi: 10.1136/bmjopen-2015-008376.
7
Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up.
Diabetes Care. 2016 May;39(5):686-93. doi: 10.2337/dc15-1990. Epub 2016 Feb 9.
8
Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
JAMA. 2015 Dec 1;314(21):2241-50. doi: 10.1001/jama.2015.16174.
9
Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010.
JAMA. 2015 Jan 6;313(1):37-44. doi: 10.1001/jama.2014.16425.
10
Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis.
Diabetes. 2015 Jun;64(6):2028-41. doi: 10.2337/db14-1225. Epub 2014 Dec 31.
Zotero 插件